Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Status:
Active, not recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of durvalumab and
tremelimumab can help to control sarcoma. The safety of this drug combination will also be
studied.
This is an investigational study. Durvalumab and tremelimumab are not FDA approved or
commercially available. They are currently being used for research purposes only. The study
doctor can explain how the study drugs are designed to work.
Up to 150 participants will be enrolled in this study. All will take part at MD Anderson.